Supporting Information

A Highly Efficient Kinetic Resolution of Morita-Baylis-Hillman Adducts Achieved by N-Ar Axially Chiral Pd-Complexes Catalyzed Asymmetric Allylation

Feijun Wang,^{1,*} Shengke Li,¹ Mingliang Qu,¹ Mei-Xin Zhao,¹ Lian-Jun Liu,¹ and Min Shi^{1,2,*}

¹Key Laboratory for Advanced Materials and Institute of Fine Chemicals, School of Chemistry & Molecular Engineering, East China University of Science and Technology, and 130 MeiLong Road, Shanghai 200237, People's Republic of China, and ²State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, People's Republic of China

feijunwang@ecust.edu.cn, Mshi@mail.sioc.ac.cn


CONTENTS

General remarks. Dichloromethane was freshly distilled from calcium hydride; THF and toluene were distilled from sodium (Na) under argon (Ar) atmosphere. Melting points were determined on a digital melting point apparatus and temperatures were uncorrected. 1 H NMR and 13 C NMR spectra were recorded on a Bruker AM-300 or AM-400 spectrophotometers. Infrared spectra were recorded on a Perkin-Elmer PE-983 spectrometer with absorption in cm $^{-1}$. Flash column chromatography was performed using 300-400 mesh silica gel. For thin-layer chromatography (TLC), silica gel plates (Huanghai GF₂₅₄) were used. Elementary analysis was taken on a Carlo-Erba 1106 analyzer. Mass spectra were recorded by EI and ESI, and HRMS were measured on a HP-5989 instrument. Optical rotations were determined at 589 nm (sodium D line) by using a Perkin-Elmer-341 MC digital polarimeter; [α]_D-values are given in unit of 10 deg $^{-1}$ cm 2 g $^{-1}$. Chiral HPLC was performed on a SHIMADZU SPD-10A vp series with chiral columns (Chiralpak AD-H, OD-H and OJ-H columns 4.6 × 250 mm, Daicel Chemical Ind., Ltd.).

Synthesis of axially chiral ligands (aS,S)-S6 and (aR,S)-S6.

Methyl 1-(trifluoromethylsulfonyloxy)-2-naphthoate S1. [1]


Trifluoromethanesulfonic anhydride (1.1 mL, 6.5 mmol) was added dropwise to the solution of methyl 1-hydroxy-2-naphthoate (1.01 g, 5.0 mmol) and pyridine (0.5 mL, 6.2 mol) in dried CH₂Cl₂ (12 mL) at 0 °C, and the resulting solution was stirred for 2 h at room temperature. The reaction mixture was diluted with CH₂Cl₂, and washed with water and saturated sodium bicarbonate solution. The organic layer was dried over MgSO₄. The solvent was removed under reduced pressure and the crude product was purified by flash chromatography (ethyl acetate/petroleum ether = 1/16) to afford **S1** as light yellow solid in 95% yield (1.59 g, 4.75 mmol). ¹H NMR(400 MHz, CDCl₃) δ 4.02 (s, 3H), 7.67-7.71 (m, 2H), 7.90-7.94 (m, 2H), 8.00 (d, J = 8.8 Hz, 1H), 8.18-8.20 (m, 1H). ¹³C NMR(100 MHz, CDCl₃) δ 52.8, 113.8, 117.0, 120.2, 121.4, 122.1, 123.4, 126.2, 128.0, 128.1, 128.2, 129.1, 136.6, 144.7, 165.3. ¹⁹F NMR(470 MHz, CDCl₃) δ -73.0; MS (ESI) m/z (%): 333.0 (M-H, 100); HRMS (Micromass LCT) Calcd. for C₁₃H₈O₅SF₃: 333.0045; Found: 333.0044.



Methyl 1-(2-nitrophenylamino)-2-naphthoate **S2**.

Methyl 1-(trifluoromethylsulfonyloxy)-2-naphthoate **S1** (0.67 g, 2.0 mmol), 2-nitroaniline (0.30 g, 2.2 mmol), Pd(OAc)₂ (22.5 mg, 0.1 mmol), DPE-phos (108.0 mg, 0.2 mmol), and Cs_2CO_3 (0.98 g, 3.0 mmol) were stirred in anhydrous toluene (10 mL) at 75 °C until the reaction was completed. The reaction mixture was cooled to room temperature, and was filtrated by diatomite. The filtrate was washed with water, extracted with DCM (3 x 20 mL) and dried over anhydrous MgSO₄. The solvent was removed under reduced pressure and the residue was purified by a silica gel flash column chromatography (ethyl acetate/petroleum ether = 1/10) to afford the desired product **S2** as orange solid in 98% yield (0.63 g, 1.96 mmol). Mp. 141.6-142.9 °C; IR (direct irradiation) ν 630, 760, 810, 890, 962, 1034, 1135, 1205, 1284, 1344, 1422,


1728, 2960, 3082 cm⁻¹; ¹H NMR (400 MHz, CDCl₃, TMS) δ 3.90 (s, 3H), 6.34 (d, J = 8.4 Hz, 1H), 6.78-6.82 (m, 1H), 7.15-7.19 (m, 1H), 7.43-7.47 (m, 1H), 7.58-7.62 (m, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.91 (t, J = 7.2 Hz, 2H), 8.05 (d, J = 8.4 Hz, 1H), 8.24 (dd, J = 1.6, 8.4 Hz, 1H), 10.48 (s, 1H); ¹³C NMR (100 MHz, CDCl₃, TMS) δ 52.4, 117.4, 118.1, 122.5, 125.5, 126.2, 126.35, 126.37, 127.0, 128.4, 128.5, 129.3, 134.4, 135.0, 136.1, 137.9, 143.3, 167.0; MS (ESI) m/z (%): 323.1 (M + H, 21); HRMS (Micromass LCT) Calcd. for C₁₈H₁₅N₂O₄: 323.1032; Found: 323.1036.




Methyl 1-(2-aminophenylamino)-2-naphthoate S3.

A mixture of **S2** (0.97 g, 3.0 mmol), 10% Pd-C (0.32 g) in a solution of MeOH (14 mL) were stirred overnight under reflux in 1 atm of H₂. After cooling to room


temperature, Pd-C was removed by filtration, and the resulting solution was evaporated to remove solvent under reduced pressure. The residue was purified by a silica gel flash column chromatography (ethyl acetate/petroleum ether = 1/10, 1% NEt₃ added) to afford the desired product **S3** as yellow solid in 99% yield (0.87 g, 2.97 mmol). Mp. 134.3-136.1 °C; IR (direct irradiation) ν 713, 740, 760, 788, 1138, 1208, 1243, 1270, 1341, 1496, 1569, 1669, 3337, 3440 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz, TMS) δ 3.93 (s, 3H), 4.06 (br s, 2H), 6.41 (d, J = 8.0 Hz, 1H), 6.47-6.51 (m, 1H), 6.81-6.89 (m, 2H), 7.20-7.25 (m, 1H), 7.41-7.48 (m, 2H), 7.77 (t, J = 8.0 Hz, 2H), 7.98 (d, J = 8.8 Hz, 1H), 9.23 (s, 1H); ¹³C NMR (CDCl₃, 100 MHz, TMS) δ 52.0, 113.6, 115.6, 118.6, 121.0, 121.4, 123.8, 125.1, 125.9, 126.5, 126.7, 128.1, 128.2, 133.2, 136.8, 139.3, 147.6, 169.1; MS (ESI) m/z (%): 293.1 (M + H, 100); HRMS (Micromass LCT) Calcd. for C₁₈H₁₇N₂O₂: 293.1290; Found: 293.1294.





Methyl 1-(1*H*-benzo[d]imidazol-1-yl)-2-naphthoate **S4**.


The compound **S3** (0.88 g, 3.0 mmol) and triethyl orthoformate [HC(OC₂H₅)₃] (8.0 mL) containing a catalytic amount of TsOH were heated at 80 °C until the compound **S3** was consumed. After cooling to room temperature, ethyl acetate was added to form an azeotropic solution in order to remove the excess amount of triethyl orthoformate under reduced pressure. The residue was purified by a silica gel flash column chromatography (ethyl acetate/petroleum ether = 1/3) to afford the desired product **S4** in 76% yield (0.69 g, 2.28 mmol). Viscous brown solid; Mp. 115.0-116.7 °C; IR (direct irradiation) ν 683, 750, 766, 1138, 1161, 1190, 1223, 1237, 1270, 1431, 1454, 1486, 1718, 2951 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz, TMS) δ 3.51 (s, 3H), 6.92 (d, J = 8.4 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.34 (t, J = 8.0 Hz, 2H), 7.49 (t, J = 8.0 Hz, 1H), 7.66 (t, J = 7.6 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 8.04 (s, 1H), 8.11 (s, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ 52.5, 110.1, 120.3, 122.5, 123.6, 123.9, 126.1, 126.9, 128.2, 128.4, 128.8, 129.7, 130.7, 132.5, 135.7, 136.1, 143.0, 144.1, 165.8; MS (ESI) m/z (%): 303.1 (M + H, 100); HRMS (Micromass LCT) Calcd. for C₁₉H₁₅N₂O₂: 303.1134; Found: 303.1134.




1-(1*H*-benzo[d]imidazol-1-yl)-*N*-((*S*)-2-hydroxy-1-phenylethyl)-2-naphthamide **S5**.

A solution of (*S*)-2-amino-2-phenylethanol (1.10 g, 8.0 mmol), compound **S4** (1.21 g, 4.0 mmol), Cs_2CO_3 (2.61 g, 8.0 mmol), and toluene (20 mL) was stirred at 85 °C until the compound **S4** was consumed. After cooling to room temperature, The mixture was diluted with DCM, and washed with cold water, and brine. The organic layer was dried over MgSO₄. After removal of the solvent in vacuo, the residue was purified by a silica gel flash column chromatography (petroleum ether/ethyl acetate, 1/1-0/1) to afford the diastereomeric mixture **S5** in 91% yield (1.48 g, 3.63 mmol). Pale red solid; Mp. 226.7-228.4 °C; IR (direct irradiation) ν 700, 742, 752, 763, 1045,

1136, 1231, 1306, 1270, 1491, 1455, 1649, 1721, 3055, 3194 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz, TMS) δ 2.23 (br s, 2H), 3.31-3.37 (m, 1H), 3.40-3.48 (m, 1H), 4.86-4.90 (m, 1H), 6.00 (d, J = 7.2 Hz, 0.50H), 6.55 (d, J = 7.6 Hz, 0.46H), 6.65-6.67 (m, 1H), 6.82-6.85 (m, 1H), 7.01 (d, J = 8.0 Hz, 0.54H), 7.04 (d, J = 8.0 Hz, 0.50H), 7.08-7.15 (m, 3H), 7.19-7.25 (m, 1H), 7.33 (t, J = 7.2 Hz, 0.52H), 7.39 (t, J = 7.6 Hz, 0.56H), 7.46 (d, J = 7.6 Hz, 0.50H), 7.50 (d, J = 8.0 Hz, 0.53H), 7.61-7.65 (m, 1H), 7.82-7.89 (m, 2H), 7.97-8.09 (m, 3H); ¹³C NMR (CDCl₃, 100 MHz, TMS) δ 55.7, 55.9, 65.4, 65.6, 110.4, 110.5, 120.5, 120.8, 123.17, 123.23, 123.3, 123.5, 124.3, 124.6, 125.3, 125.5, 126.32, 126.35, 127.57, 127.63, 128.2, 128.29, 128.36, 128.39, 128.46, 128.50, 128.6, 128.7, 128.8, 130.1, 130.22, 130.24, 130.41, 132.83, 132.86, 134.80, 134.84, 135.6, 135.8, 138.2, 142.8, 143.1, 143.9, 144.4, 166.3, 166.5; MS (ESI) m/z (%): 408.2 (M + H, 100); HRMS (Micromass LCT) Calcd. for C₂₆H₂₂N₃O₂: 408.1712; Found: 408.1715.






(S)-2-((S)-1-(1H-benzo[d]imidazol-1-yl)naphthalen-2-yl)-4-phenyl-4,5-dihydrooxazol e (aS,S)-**S6** and (S)-2-((R)-1-(1H-benzo[d]imidazol-1-yl)naphthalen-2-yl)-4-phenyl-4,5-dihydrooxazole (aR,S)-**S6**.

SOCl₂ (0.36 mL, 5.1 mol) was slowly added to a solution of diastereomeric mixture **S5** (0.41 g, 1.0 mol) and dried 1,2-dichloroethane (10 mL) at 0 °C. The resulting solution was stirred at 40 °C for 4 h, and then the solvent was removed under reduced pressure. Subsequently, the residue was treated with sodium methoxide (0.43 g, 8.0 mol) in CH₃OH (15 mL), and stirred overnight under reflux. The resulting mixture was diluted with cold water, and extracted with DCM (3 x 20 mL). The organic layer was washed with brine, and dried over Na₂SO₄. After removal of the solvent under reduced pressure, the residue was purified by a silica gel flash column chromatography (ethyl acetate/petroleum ether = 1/2) to afford (a*S*,*S*)-**S6** (144.1 mg, 0.37 mmol) and (a*R*,*S*)-**S6** (171.4 mg, 0.44 mmol).


(a*S*,*S*)-**S6**: White solid, 37% yield; Mp. 186.1-187.9 °C; IR (direct irradiation) ν 683, 698, 748, 759, 831, 971, 1008, 1106, 1224, 1454, 1471, 1645, 2898, 3073 cm⁻¹; $[\alpha]^{20}_{D} = +112.1$ (c 0.70, CHCl₃); ¹H NMR (CDCl₃, 400 MHz, TMS) δ 3.90 (t, J = 8.8 Hz, 1H), 4.29 (dd, J = 8.4, 10.4 Hz, 1H), 5.15 (dd, J = 8.8, 10.4 Hz, 1H), 6.85-6.87 (m, 2H), 6.99 (d, J = 8.0 Hz, 1H), 7.19-7.24 (m, 4H), 7.34-7.38 (m, 2H), 7.47-7.51 (m, 1H), 7.63-7.67 (m, 1H), 7.94 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 8.10 (d, J = 8.4 Hz, 2H), 8.17 (d, J = 8.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz, TMS) δ 69.7, 74.8, 110.3, 120.3, 122.5, 123.57, 123.58, 124.6, 126.3, 126.5, 127.4, 128.25, 128.32, 128.4

128.6, 129.7, 130.9, 131.7, 135.3, 136.0, 141.5, 143.2, 144.4, 162.9; MS (ESI) m/z (%): 390.2 (M + H, 71); HRMS (Micromass LCT) Calcd. for $C_{16}H_{20}N_3O$: 390.1606; Found: 390.1611.



(aR,S)-**S6**: White solid, 44% yield; Mp. 153.6-155.4 °C; $[\alpha]^{20}_D = -62.5$ (c 0.80, CHCl₃); ¹H NMR (CDCl₃, 400 MHz, TMS) δ 3.64 (t, J = 8.8 Hz, 1H), 4.43 (dd, J = 8.8, 10.0 Hz, 1H), 5.14 (dd, J = 9.2, 10.4 Hz, 1H), 6.92-6.94 (m, 2H), 7.02 (d, J = 8.0 Hz, 1H), 7.21-7.25 (m, 4H), 7.33-7.37 (m, 1H), 7.39 (d, J = 8.8 Hz, 1H), 7.47-7.52 (m, 1H), 7.62-7.67 (m, 1H), 7.94 (d, J = 8.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 10.4 Hz, 2H), 8.15 (d, J = 8.8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz, TMS) δ 69.8, 75.2, 110.4, 120.3, 122.5, 123.5, 123.6, 124.9, 126.6, 126.7, 127.6, 128.28, 128.32, 128.4, 128.6, 129.7, 130.8, 131.7, 135.3, 136.1, 141.3, 143.1, 144.4, 163.5; MS (ESI)

m/z (%): 390.2 (M + H, 71); HRMS (Micromass LCT) Calcd. for $C_{16}H_{20}N_3O$: 390.1606; Found: 390.1611.





Synthesis of axially chiral Pd complexes (aS,S)-2.

The compound (aS,S)-**S6** (0.58 g, 1.49 mmol) and RI (15 mmol) in CH₃CN (10 mL) were stirred under reflux until the compound (aS,S)-**S6** was consumed. After


cooling to room temperature, volatiles were removed under reduced pressure to obtain the crude benzimidazolium salt (aS,S)-S7. Salt (aS,S)-S7, Pd $(OAc)_2$ (0.33 g, 1.47 mmol) and KI (0.50 g, 3.0 mmol) were refluxed in THF (25 mL) for 8 h. The volatiles were then removed under reduced pressure and the residue was purified by a silica gel flash column chromatography (dichloromethane/petroleum ether = 6/1-1/0) to give (aS,S)-2 as earth yellow solid.

Complex (a*S*,*S*)-**2a** (R = Me, 806.7 mg, 71% yield): Mp. > 250 °C; $[\alpha]^{20}_D$ = +65.8 (c 0.50, CHCl₃); A single crystal of (a*S*,*S*)-**2a** suitable for X-ray crystal analysis was obtained by recrystallization from a saturated solution of CH₂Cl₂/petroleum ether (1/1, v/v). ¹H NMR (CDCl₃, 400 MHz, TMS) δ 3.46 (s, 3H), 4.63 (dd, J= 5.6, 9.2 Hz, 1H), 5.06 (t, J= 9.6 Hz, 1H), 6.13 (dd, J= 5.6, 10.4 Hz, 1H), 6.64 (d, J= 8.4 Hz, 1H), 6.92 (d, J= 7.2 Hz, 2H), 7.16 (t, J= 8.0 Hz, 2H), 7.18-7.23 (m, 1H), 7.37-7.43 (m, 4H), 7.49 (t, J= 8.0 Hz, 1H), 7.70 (t, J= 7.2 Hz, 1H), 7.96 (d, J= 8.4 Hz, 1H), 8.10 (d, J= 8.4 Hz, 1H), 8.29 (d, J= 8.4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz, TMS) δ 29.6, 36.0, 70.7, 110.7, 112.1, 121.5, 124.3, 124.55, 124.63, 127.2, 128.5, 128.91, 128.94, 129.1, 129.3, 129.5, 130.8, 132.5, 134.3, 135.0, 136.0, 139.0, 163.1, 173.5; MS (ESI) m/z (%): 636.0 (M-I, 100); HRMS (Micromass LCT) Calcd. for C₂₇H₂₁IN₃OPd: 635.9764; Found: 635.9764.





Complex (a*S*,*S*)-**4b** (R = Et, 417.6 mg, 36% yield): Mp. > 250 °C; $[\alpha]^{20}_{D}$ +20.8 (*c* 0.74, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 1.36 (t, J = 7.2 Hz, 3 H), 3.50-3.59 (m, 1H), 4.53-4.62 (m, 2H), 5.04 (t, J = 9.6 Hz, 1 H), 6.16 (dd, J = 5.6, 10.0 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1 H), 6.89 (d, J = 7.2 Hz, 2 H), 7.14 (t, J = 7.6 Hz, 2 H), 7.20 (t, J = 8.0 Hz, 1 H), 7.34-7.47 (m, 4H), 7.53 (t, J = 8.0 Hz, 1 H), 7.73 (t, J = 7.2 Hz, 1 H), 7.98 (d, J = 8.8 Hz, 1 H), 8.12 (d, J = 8.4 Hz, 1 H), 8.27 (d, J = 8.4 Hz, 1 H). MS (ESI) m/z (%): 650.0 (M-I, 100); HRMS (Micromass LCT) Calcd. for $C_{28}H_{23}IN_3OPd$: 649.9921; Found: 649.9905.



Complex (a*S*,*S*)-**4c** (R = *i*-Pr, 355.2 mg, 30% yield): Mp. > 250 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.75 (d, J = 7.2 Hz, 3H), 1.65 (d, J = 7.2 Hz, 3H), 4.57 (dd, J = 5.2, 8.8 Hz, 1H), 5.03 (t, J = 10.0 Hz, 1H), 5.73-5.80 (m, 1H), 6.25 (dd, J = 5.2, 9.2 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 7.6 Hz, 2H), 7.10 (t, J = 7.6 Hz, 2H), 7.17 (t, J = 8.0 Hz, 1H), 7.23 (d, J = 7.6 Hz, 2H), 7.35 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 19.5, 20.8, 29.7, 55.9, 70.8, 112.7, 113.2, 121.4, 123.9, 124.4, 125.1, 126.9, 128.5, 128.8, 128.9, 129.2, 129.4, 129.5, 130.8, 131.9, 132.6, 136.2, 136.3, 138.8, 164.0, 172.5, 207.1. MS (ESI) m/z (%): 636.0 (M-I, 100); HRMS (Micromass LCT) Calcd. for C₂₉H₂₅IN₃OPd: 664.0077; Found: 664.0073.




Table S1 Screening of the amount of PhB(OH)₂ and NEt₃.^a

| • | | | a b | 5aa | | Recovered 3a | |
|-------|--------------------------------|-------------------------------|---------------------------|---------------------------|------------------------|---------------------------|------------------------|
| Entry | amount of PhB(OH) ₂ | amount of NEt ₃ | Conv. ^b [%] | Yield ^c [%] | ee ^d [%] | Yield ^c [%] | ee ^e [%] |
| 1 | 0.5 equiv | 0.5 equiv | 35 | 34 | 97 | 63 | 41 |
| 2 | 1.0 equiv | 0.5 equiv | 40 | 39 | 93 | 58 | 73 |
| 3 | 3.0 equiv | 0.5 equiv | 43 | 40 | 94 | 55 | 53 |
| 4 | 1.0 equiv | 0.25 equiv | 40 | 35 | 93 | 56 | 70 |
| 5 | 3.0 equiv | 1.5 equiv | 20 | 38 | 96 | 68 | 16 |

^a Reaction conditions: 1.0 mL CH₃CN, 0.1 mmol **3a**, 153 mol% Pd complex, 15 mol% AgOTf, RT, 24 h. ^b Determined by crude ¹H NMR spectra. ^c Isolated yields. ^d The enantioselectivity of (*E*)-**5aa** was determined by chiral HPLC analysis. ^e Determined by chiral HPLC analysis.

General procedure for the Pd(II)-catalyzed asymmetric allylic alkylation of 4 with 3.


(a*S*,*S*)-2a (15 mol%, 11.5 mg, 0.015 mmol) and AgOTf (15 mol%, 3.9 mg, 0.015 mmol) were stirred in CH₃CN (1.0 mL) for 10 minutes. Then, racemic allylic alcohol 3 (0.1 mmol), arylboronic acid 4 (0.2 mmol), and triethylamine (0.05 mmol) were added and the reaction mixture was stirred at room temperature for 24 h. The solvent was evaporated under reduced pressure and the residue was purified by chromatography on silica gel to obtain the allylic alkylation product 5 and recovered alcohol 3. The enantioselectivities of compound (*E*)-5 and recovered alcohol 3 were determined by HPLC on a chiral stationary phase.


(R,E)-2-Benzylidene-3-phenylcyclohexanone **5aa**^[2] (Table 1, entry 5): $[\alpha]_D^{20}$ +149.4 (c 0.38, CHCl₃) for 98 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.69-1.76 (m, 2H), 2.08-2.13 (m, 2H), 2.41-2.50 (m, 1H), 2.65-2.67 (m, 1H), 4.51 (t, J = 3.6 Hz, 1H), 7.16-7.28 (m, 8H), 7.33-7.36 (m, 2H), 7.59 (s, 1H). Chiralcel OJ, hexane/i-PrOH = 97/3, 0.8 mL/min, 230 nm, t_{major} = 12.74 min, t_{minor} = 20.11 min.


Table S2 Screening of chiral Pd-complexes.^a

| Entry Pd complex | 7a , Yield ^b [%] |
|---|---------------------------------------|
| 1° (aS,S)- 6a , AgOTf | 11 |
| 2 ^c (aS,S)- 6b , AgOTf | 55 |
| 3 (aS,S)- 6c , Pd(OTf) ₂ | 13 |
| 4 ^d Trost ligand, Pd(OTf) ₂ | trace |


 $[^]a$ Reaction conditions: 1.0 mL CH₃CN, 0.1 mmol **3a**, 0.2 mmol **4a**, 3 mol% Pd complex, 0.05 mmol KOH, 50 °C, 24 h. b Isolated yields. c 3 mol% AgOTf. d 15 mol% Pd complex, 15 mol% AgOTf.









(*S*)-2-(hydroxy(phenyl)methyl)cyclohex-2-enone 3a.^[3] [α]_D²⁰ +9.3 (*c* 0.80, CH₂Cl₂) for 61 % ee (Fig. 2, entry 8). ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.97-2.05 (m, 2H), 2.37-2.41 (m, 2H), 2.44-2.47 (m, 2H), 3.47 (br s, 1H), 5.56 (s, 1H), 6.73 (t, J = 4.4 Hz, 1H), 7.25-7.37 (m, 5H). Chiralcel OJ, hexane/*i*-PrOH = 90/10, 1.0 mL/min, 254 nm, t_{major} = 19.72 min, t_{minor} = 17.86 min.








(*E*)-2-benzylidenecyclohex-3-enone **7a** (Table 1, entries 6-8):^[4] ¹H NMR (400 MHz, CDCl₃, TMS): δ 2.57-2.62 (m, 2H), 2.66-2.70 (m, 2H), 6.13-6.18 (m, 1H), 6.93 (dd, *J* = 0.8, 10.0 Hz, 1H), 7.31-7.34 (m, 1H), 7.37-7.41 (m, 2H), 7.42-7.44 (m, 3H).




(R,E)-2-benzylidene-3-o-tolylcyclohexanone **5ab** (Fig. 2, entry 1): $[\alpha]_D^{20}$ +16.8 (c 0.25, CHCl₃) for 93 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.73-2.02 (m, 4H), 2.38 (s, 3H), 2.44-2.54 (m, 1H), 2.74-2.79 (m, 1H), 4.56 (br s, 1H), 6.94 (d, J = 7.6 Hz, 1H), 7.07-7.25 (m, 8H), 7.57 (s, 1H); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.9, 22.7, 31.9, 40.6, 44.4, 126.1, 126.5, 128.3, 128.56, 128.59, 129.8, 131.2, 134.7, 135.2, 136.9, 139.9, 142.8, 203.1. Chiralcel AD, hexane/i-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 12.95 min, t_{minor} = 7.29 min.









(*R*,*E*)-2-Benzylidene-3-*m*-tolylcyclohexanone **5ac** (Fig. 2, entry 2): $[\alpha]_D^{20}$ +152.4 (*c* 0.50, CHCl₃) for 95 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.70-1.76 (m, 2H), 2.04-2.12 (m, 2H), 2.35 (s, 3H), 2.40-2.49 (m, 1H), 2.65-2.71 (m, 1H), 4.47 (t, *J* = 3.6 Hz, 1H), 7.00-7.02 (m, 2H), 7.06 (d, *J* = 7.2 Hz, 1H), 7.17-7.20 (m, 2H), 7.21-7.23 (m, 1H), 7.25-7.28 (m, 3H), 7.57 (s, 1H); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.8, 21.6, 32.2, 40.5, 43.2, 124.9, 127.3, 128.3, 128.4, 128.67, 128.71, 130.1, 135.1, 136.9, 138.4, 139.3, 144.0, 203.2. MS (ESI) m/z (%): 277.2 (M+H, 17.8); HRMS (Micromass LCT) Calcd. for C₂₀H₂₁O: 277.1592; Found: 277.1597. Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.5 mL/min, 254 nm, t_{major} = 11.96 min, t_{minor} = 10.61 min.







| | Σ : Sample | RetTime (min) | 545350 Hight | 7501002. 3 Area | 100. 0000 Area (%) | Tailing factor | Theoretical plates (N) |
|-------------------|-------------------|---------------|-----------------|--------------------|-----------------------|----------------|----------------------------|
| 2 | | 11.955 | 530777 | 7320247.3 | 97. 5903 | 1.17 | 14976 |
| 1 | | 10.607 | 14573 | 180755.0 | 2.4097 | 1.13 | 14575 |
| ID | 组分名 | 保留时间 | 峰高 | 峰面积 | 浓度 | 拖尾因子 | 理论塔板 |
| -63. 00 0. 000 | 1. 500 3. 000 | 4, 500 | 6.000 | 7.500 9.00 | | 12.000 | 13, 500 15, 000 Minute: |
| 237. 40 | | | | | la et | | |
| 537. 80 | | | | | | 8 | |
| 838. 20 | | | | | | | |
| 1138, 60 | | | | | | | |


(*R,E*)-2-Benzylidene-3-*p*-tolylcyclohexanone **5ad**^[2] (Fig. 2, entry 3): $[\alpha]_D^{20}$ +67.1 (*c* 0.35, CHCl₃) for 95 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.69-1.76 (m, 2H), 2.06-2.10 (m, 2H), 2.35 (s, 3H), 2.40-2.49 (m, 1H), 2.64-2.69 (m, 1H), 4.47 (t, *J* = 3.6 Hz, 1H), 7.10 (d, *J* = 8.0 Hz, 2H), 7.14-7.20 (m, 4H), 7.25-7.27 (m, 3H), 7.56 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.8, 21.0, 32.2, 40.5, 42.9, 127.7, 128.3, 128.7, 129.5, 130.1, 135.1, 136.0, 136.8, 139.5, 140.9, 203.2. MS (ESI) *m/z* (%): 277.2 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₂₀H₂₁O: 277.1592; Found: 277.1588. Chiralcel OD, hexane/*i*-PrOH = 90/10, 0.7 mL/min, 254 nm, t_{major} = 12.15 min, t_{minor} = 7.04 min.










(*R,E*)-2-Benzylidene-3-(3-chlorophenyl)cyclohexanone **5ae**. (Fig. 2, entry 4): $[\alpha]_D^{20}$ +47.1 (*c* 0.39, CHCl₃) for 97 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.64-1.80 (m, 2H), 2.09-2.13 (m, 2H), 2.41-2.50 (m, 1H), 2.65-2.71 (m, 1H), 4.48 (br s, 1H), 7.09 (d, *J* = 7.2 Hz, 1H), 7.14-7.16 (m, 2H), 7.22-7.30 (m, 6H), 7.61 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 32.1, 40.3, 43.1, 126.1, 126.9, 127.9, 128.5, 129.0, 130.0, 130.1, 134.80, 134.83, 137.7, 138.3, 146.2, 209.3. MS (ESI) *m/z* (%): 297.1 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₁₉H₁₈ClO: 297.1046; Found: 297.1049. Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{maijor} = 8.74 min, t_{minor} = 7.92 min.









(R,E)-2-benzylidene-3-(4-chlorophenyl)cyclohexanone **5af**. (Fig. 2, entry 5): $[\alpha]_D^{20}$ +267.9 (c 0.47, CHCl₃) for 98 % ee. 1 H NMR (400 MHz, CDCl₃, TMS): δ 1.62-1.79 (m, 2H), 2.07-2.12 (m, 2H), 2.41-2.48 (m, 1H), 2.65-2.70 (m, 1H), 4.47 (t, J = 3.2 Hz, 1H), 7.13-7.16 (m, 4H), 7.20-7.25 (m, 1H), 7.27-7.28 (m, 2H), 7.32 (dd, J = 1.6, 6.4 Hz, 2H), 7.59 (s, 1H). 13 C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 32.1, 40.4, 42.8, 128.4, 128.9, 129.0, 129.2, 129.9, 132.3, 134.8, 137.5, 138.6, 142.5, 202.7. MS (ESI) m/z (%): 297.1 (M+H, 38); HRMS (Micromass LCT) Calcd. for $C_{19}H_{18}$ ClO: 297.1046; Found: 297.1049. Chiralcel OJ, hexane/i-PrOH = 97/3, 0.8 mL/min, 230 nm, t_{major} = 17.84 min, t_{minor} = 14.13 min.







(R,E)-2-Benzylidene-3-(2-methoxyphenyl)cyclohexanone **5ag**. (Fig. 2, entry 6): $[\alpha]_D^{20}$ +37.2 (c 0.52, CHCl₃) for 94 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.73-1.81

(m, 2H), 1.93-2.06 (m, 2H), 2.42-2.51 (m, 1H), 2.64-2.75 (m, 1H), 3.86 (s, 3H), 4.74 (t, J = 4.4 Hz, 1H), 6.87-7.00 (m, 3H), 7.13-7.16 (m, 2H), 7.22-7.25 (m, 4H), 7.52 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 19.5, 30.0, 38.9, 40.6, 55.3, 111.0, 120.6, 127.7, 128.2, 128.6, 129.5, 130.2, 132.9, 135.2, 136.3, 139.8, 156.4, 203.3. MS (ESI) m/z (%): 297.1 (M, 100); HRMS (Micromass LCT) Calcd. for C₂₀H₂₀O₂: 292.1463; Found: 292.1467. Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 12.76 min, t_{minor} = 9.08 min.










(*R*,*E*)-2-Benzylidene-3-(naphthalen-2-yl)cyclohexanone **5ah**. (Fig. 2, entry 7): $[\alpha]_D^{20}$ +25.4 (*c* 1.20, CHCl₃) for 98 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.62-1.75


(m, 2H), 2.15-2.27 (m, 2H), 2.44-2.53 (m, 1H), 2.68-2.74 (m, 1H), 4.65 (br s, 1H), 7.17-7.23 (m, 5H), 7.41 (dd, J = 1.6, 8.4 Hz, 1H), 7.45-7.50 (m, 2H), 7.57 (s, 1H), 7.67 (s, 1H), 7.79-7.89 (m, 3H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 31.8, 40.5, 43.5, 53.4, 121.7, 125.8, 126.0, 126.3, 126.6, 127.6, 127.9, 128.4, 128.8, 130.1, 131.2, 133.4, 137.4, 138.0, 139.0, 141.4, 203.1. MS (ESI) m/z (%): 313.2 (M+H, 62); HRMS (Micromass LCT) Calcd. for $C_{23}H_{21}O$: 313.1592; Found: 313.1594. Chiralcel OD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 9.76 min, t_{minor} = 8.15 min.










(R,E)-2-benzylidene-3-(biphenyl-4-yl)cyclohexanone **5ai**. (Fig. 2, entry 8): $[\alpha]_D^{20}$ +134.8 (c 0.77, CHCl₃) for 99 % ee. 1 H NMR (400 MHz, CDCl₃, TMS): δ 1.75-1.80 (m, 2H), 2.11-2.16 (m, 2H), 2.43-2.52 (m, 1H), 2.68-2.73 (m, 1H), 4.55 (br s, 1H), 7.20-7.22 (m, 2H), 7.25-7.29 (m, 5H), 7.34 (t, J = 7.2 Hz, 1H), 7.44 (t, J = 7.2 Hz, 2H), 7.57-7.61 (m, 5H). 13 C NMR (100 MHz, CDCl₃, TMS): δ 18.8, 32.2, 40.5, 43.1, 127.0, 127.3, 127.5, 128.2, 128.4, 128.8, 130.1, 135.0, 137.1, 139.2, 139.3, 140.6, 143.0, 203.0. MS (ESI) m/z (%): 377.1 (M+K, 20); HRMS (Micromass LCT) Calcd. for $C_{25}H_{22}$ KO: 377.1308; Found: 377.1329. Chiralcel OD, hexane/i-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 12.02 min, t_{minor} = 8.83 min.










(R,E)-4-((2-oxo-6-phenylcyclohexylidene)methyl)benzonitrile **5ba** (Fig. 2, entry 9): $[\alpha]_D^{20}$ +127.6 (c 0.30, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.70-1.77 (m, 2H), 2.10-2.13 (m, 2H), 2.43-2.52 (m, 1H), 2.70-2.75 (m, 1H), 4.40 (br s, 1H), 7.17 (d, J = 7.6 Hz, 2H), 7.22-7.29 (m, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.52 (d, J = 5.6 Hz, 2H), 7.55 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 32.2, 40.6, 43.5, 111.9, 118.5, 126.8, 127.6, 129.0, 130.2, 132.0, 134.5, 139.6, 141.9, 143.3, 202.6. MS (EI) m/z (%): 288.1 (M+H, 100); HRMS (Micromass LCT) Calcd. for $C_{20}H_{18}NO$: 288.1388; Found: 288.1376. Chiralcel AD, hexane/i-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 20.81 min, t_{minor} = 22.30 min.







(*S*)-2-(hydroxy(4-isocyanophenyl)methyl)cyclohex-2-enone **3b**.^[5] [α]_D²⁰ +31.3 (*c* 0.60, CH₂Cl₂) for 70 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.99-2.04 (m, 2H), 2.43-2.47 (m, 4H), 3.53 (br s, 1H), 5.56 (s, 1H), 6.80 (t, *J* = 4.0 Hz, 1H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.63 (d, *J* = 8.4 Hz, 2H). Chiralcel OJ, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, t_{major} = 64.87 min, t_{minor} = 55.65 min.







(*R,E*)-2-(4-methylbenzylidene)-3-phenylcyclohexanone **5ca** (Fig. 2, entry 10): $[\alpha]_D^{20}$ +167.9 (*c* 0.41, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.68-1.75 (m, 2H), 2.08-2.12 (m, 2H), 2.31 (s, 3H), 2.41-2.50 (m, 1H), 2.65-2.70 (m, 1H), 4.51 (br s, 1H), 7.06-7.12 (m, 4H), 7.21-7.27 (m, 3H), 7.35 (t, *J* = 7.6 Hz, 2H), 7.58 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 21.3, 32.2, 40.4, 43.4, 126.4, 127.9, 128.8, 129.1, 130.2, 132.1, 137.3, 138.3, 139.1, 144.1, 203.0. MS (EI) *m/z* (%): 276.2 (M, 100); HRMS (Micromass LCT) Calcd. for C₂₀H₂₀O: 276.1514; Found: 276.1513. Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 13.66 min, t_{minor} = 12.20 min.










(*S*)-2-(hydroxy(p-tolyl)methyl)cyclohex-2-enone 3c.^[6] [α]_D²⁰ +2.7 (*c* 1.0, CH₂Cl₂) for 36 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.97-2.00 (m, 2H), 2.33 (s, 3H), 2.36-2.46 (m, 4H), 3.43 (br s, 1H), 5.52 (s, 1H), 6.75 (t, J = 4.4 Hz, 1H), 7.14 (d, J = 7.6 Hz, 2H), 7.24 (d, J = 7.6 Hz, 2H). Chiralcel AS, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, t_{major} = 15.55 min, t_{minor} = 19.13 min.






(R,E)-2-(4-methoxybenzylidene)-3-phenylcyclohexanone **5da** (Fig. 2, entry 11). $[\alpha]_D^{20}$ +323.4 (c 1.0, CHCl₃) for 98 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.69-1.74 (m, 2H), 2.09-2.13 (m, 2H), 2.40-2.49 (m, 1H), 2.63-2.70 (m, 1H), 3.77 (s, 3H), 4.50 (br s, 1H), 6.78 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 7.22-7.25 (m, 3H), 7.33-7.37 (m, 2H), 7.59 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 32.3, 40.2, 43.4, 55.2, 113.9, 126.5, 127.9, 128.8, 130.4, 132.1, 136.9, 137.3, 144.1, 160.1, 202.7. MS (EI) m/z (%): 292.1 (M, 100); HRMS (Micromass LCT) Calcd. for C₂₀H₂₀O₂: 292.1463; Found: 292.1465. Chiralcel AD, hexane/i-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 16.44 min, t_{minor} = 18.99 min.










(S)-2-(hydroxy(4-methoxyphenyl)methyl)cyclohex-2-enone 3d. [7] [α]_D²⁰ +0.4 (c 1.2, CH₂Cl₂) for 32 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.98-2.02 (m, 2H),


2.37-2.46 (m, 4H), 3.38 (br s, 1H), 3.80 (s, 3H), 5.51 (s, 1H), 7.74 (t, J = 4.4 Hz, 1H), 6.85-6.88 (m, 2H), 7.25-7.28 (m, 2H). Chiralcel AS, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, $t_{major} = 53.45$ min, $t_{minor} = 48.04$ min.






(R,E)-2-(3-chlorobenzylidene)-3-phenylcyclohexanone **5ea** (Fig. 2, entry 12): $[\alpha]_D^{20}$ +106.0 (c 0.37, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.71-1.78 (m, 2H), 2.08-2.12 (m, 2H), 2.41-2.51 (m, 1H), 2.67-2.73 (m, 1H), 4.44 (t, J = 3.6 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 7.15-7.19 (m, 4H), 7.22-7.27 (m, 2H), 7.33-7.37 (m, 2H), 7.49 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 32.3, 40.5, 43.4, 126.6, 127.7, 127.9, 128.6, 128.9, 129.5, 129.8, 134.2, 135.3, 136.8, 140.5, 143.8, 202.7. MS (EI) m/z (%): 297.1 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₁₉H₁₈ClO: 297.1046; Found: 297.0949. Chiralcel AD, hexane/i-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 7.57 min, t_{minor} = 6.68 min.










(S)-2-((3-chlorophenyl)(hydroxy)methyl)cyclohex-2-enone $3e^{[6]}$ [α]_D²⁰ +10.7 (c 1.1, CH₂Cl₂) for 48 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.98-2.03 (m, 2H),


2.39-2.47 (m, 4H), 3.54 (br s, 1H), 5.51 (s, 1H), 6.77 (t, J = 4.0 Hz, 1H), 7.22-7.27 (m, 3H), 7.35 (s, 1H). Chiralcel OJ, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, $t_{major} = 19.25$ min, $t_{minor} = 17.38$ min.






(*R,E*)-2-(2-chlorobenzylidene)-3-phenylcyclohexanone **5fa** (Fig. 2, entry 13): $[\alpha]_D^{20}$ +78.8 (*c* 0.10, CHCl₃) for 98 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.71-1.75 (m, 2H), 2.09-2.10 (m, 2H), 2.46-2.55 (m, 1H), 2.68-2.72 (m, 1H), 4.32 (br s, 1H), 6.85 (d, *J* = 7.6 Hz, 1H), 7.01 (t, *J* = 7.6 Hz, 1H), 7.14-7.25 (m, 4H), 7.32-7.39 (m, 3H), 7.61 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.9, 32.2, 40.7, 43.4, 126.2, 126.5, 127.7, 128.8, 129.5, 129.7, 130.1, 133.2, 133.6, 134.9, 141.1, 143.9, 203.2. MS (EI) m/z (%): 297.1 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₁₉H₁₇ClO: 296.0968; Found: 296.0981. Chiralcel OD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 8.53 min, t_{minor} = 9.42 min.










(*R*)-2-((2-chlorophenyl)(hydroxy)methyl)cyclohex-2-enone **3f**. [4] $[\alpha]_D^{20}$ -5.6 (*c* 1.0, CH₂Cl₂) for 30 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.97-2.04 (m, 2H),


2.33-2.38 (m, 2H), 2.48-2.52 (m, 2H), 3.71 (br s, 1H), 5.95 (s, 1H), 6.48 (t, J = 4.0 Hz, 1H), 7.22-7.26 (m, 1H), 7.30-7.35 (m, 2H), 7.62 (dd, J = 1.6, 7.6 Hz, 1H). Chiralcel OD, hexane/i-PrOH = 90/10, 0.8 mL/min, 230 nm, t_{major} = 17.92 min, t_{minor} = 16.05 min.






(R,E)-2-(2,4-dichlorobenzylidene)-3-phenylcyclohexanone **5ga** (Fig. 2, entry 14): $[\alpha]_D^{20}$ +51.6 (c 0.2, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.67-1.77 (m, 2H), 2.09-2.12 (m, 2H), 2.45-2.55 (m, 1H), 2.68-2.73 (m, 1H), 4.26 (br s, 1H), 6.77 (d, J = 8.4 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 7.13 (d, J = 7.6 Hz, 2H), 7.23-7.27 (m, 1H), 7.34 (t, J = 7.6 Hz, 2H), 7.40 (s, 1H), 7.53 (s, 1H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.9, 32.3, 40.7, 43.6, 126.6, 127.6, 128.9, 129.4, 130.8, 132.10, 132.13, 134.9, 135.7, 141.5, 143.7, 202.8. MS (EI) m/z (%): 331.0 (M+H, 100); HRMS (Micromass LCT) Calcd. for $C_{19}H_{17}Cl_2O$: 331.0656; Found: 331.0477. Chiralcel OJ, hexane/i-PrOH = 97/3, 0.8 mL/min, 230 nm, t_{major} = 9.19 min, t_{minor} = 12.78 min.







(*R*)-2-((2,4-dichlorophenyl)(hydroxy)methyl)cyclohex-2-enone **3g**. [6] $[\alpha]_D^{20}$ -5.4 (*c* 1.0, CH₂Cl₂) for 34 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.99-2.04 (m, 2H),


2.34-2.37 (m, 2H), 2.48-2.52 (m, 2H), 3.71 (br s, 1H), 5.88 (s, 1H), 6.49 (t, J = 4.0 Hz, 1H), 7.31 (dd, J = 2.4, 8.8 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.57 (d, J = 8.8 Hz, 1H). Chiralcel OD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, $t_{major} = 9.56$ min, $t_{minor} = 12.02$ min.







(*R*,*E*)-3-(4-chlorophenyl)-2-(4-nitrobenzylidene)cyclohexanone **5hf** (Fig. 2, entry 15): A pale yellow solid; $[\alpha]_D^{20}$ +815.0 (*c* 0.28, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.66-1.84 (m, 2H), 2.09-2.14 (m, 2H), 2.44-2.53 (m, 1H), 2.68-2.75 (m, 1H), 4.38 (br s, 1H), 7.12 (d, *J* = 8.0 Hz, 2H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.33-7.36 (m, 2H), 7.56 (s, 1H), 8.11-8.13 (m, 2H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.6, 32.1, 40.5, 43.0, 123.6, 129.0, 129.3, 130.4, 132.8, 134.4, 141.3, 141.7, 141.8, 147.4, 202.2. MS (EI) m/z (%): 342.1 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₁₉H₁₇ClNO₃: 342.0897; Found: 342.0900. Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 25.17 min, t_{minor} = 20.41 min.










(*S*)-2-(hydroxy(4-nitrophenyl)methyl)cyclohex-2-enone **3h**.^[8] [α]_D²⁰ +36.4 (*c* 0.8, CH₂Cl₂) for 90 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.98-2.05 (m, 2H), 2.42-2.48 (m, 4H), 3.58 (br s, 1H), 5.61 (s, 1H), 6.83 (t, J = 4.0 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 8.17-8.21 (m, 2H). Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, t_{major} = 27.12 min, t_{minor} = 30.36 min.







(R,E)-2-ethylidene-3-phenylcyclohexanone **5ia**^[2] (Fig. 2, entry 16): $[\alpha]_D^{20}$ +38.0 (c 0.60, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.58 (d, J = 6.8 Hz, 3H), 1.69-1.75 (m, 2H), 1.96-2.01 (m, 1H), 2.07-2.14 (m, 1H), 2.35-2.44 (m, 1H), 2.52-2.58 (m, 1H), 4.74 (br s, 1H), 6.95 (q, J = 7.2 Hz, 1H), 7.12 (d, J = 7.6 Hz, 2H), 7.19 (t, J = 7.2 Hz, 1H), 7.27 (d, J = 7.6 Hz, 2H). Chiralcel AD, hexane/i-PrOH = 90/10, 0.7 mL/min, 254 nm, t_{major} = 8.64 min, t_{minor} = 9.38 min.










(*R*)-2-(1-hydroxyethyl)cyclohex-2-enone **3i**.^[9] [α]_D²⁰ +0.7 (*c* 0.6, CH₂Cl₂) for 91 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 1.34 (d, J = 5.6 Hz, 3H), 1.97-2.03 (m, 2H), 2.39-2.47 (m, 4H), 2.76 (br s, 1H), 4.58 (dd, J = 6.4, 12.8 Hz, 1H), 6.93 (t, J = 4.0 Hz, 1H). Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.8 mL/min, 230 nm, t_{major} = 13.30 min, t_{minor} = 11.43 min.






(*R,E*)-2-(cyclohexylmethylene)-3-phenylcyclohexanone **5ja** (Fig. 2, entry 17): $[\alpha]_D^{20}$ +104.3 (*c* 0.50, CHCl₃) for 99 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 0.86-0.99 (m, 3H), 1.08-1.23 (m, 4H), 1.50-1.61 (m, 2H), 1.68-1.73 (m, 3H), 1.99-2.13 (m, 3H), 2.34-2.43 (m, 1H), 2.51-2.58 (m, 1H), 4.27 (t, *J* = 4.8 Hz, 1H), 6.58 (dd, *J* = 0.8, 10.0 Hz, 1H), 7.13 (d, *J* = 7.2 Hz, 2H), 7.16-7.20 (m, 1H), 7.25-7.29 (m, 2H). ¹³C NMR (100 MHz, CDCl₃, TMS): δ 18.7, 25.3, 25.4, 25.7, 31.0, 32.0, 32.3, 37.1, 40.0, 41.8, 126.1, 127.7, 128.3, 136.6, 144.9, 146.9, 202.3. MS (EI) m/z (%): 268.2 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₁₉H₂₄O: 268.1827; Found: 268.1838. Chiralcel AD, hexane/*i*-PrOH = 90/10, 0.5 mL/min, 254 nm, t_{major} = 10.99 min, t_{minor} = 9.19 min.







(*R*)-2-(cyclohexyl(hydroxy)methyl)cyclohex-2-enone $\bf 3j$. [α]_D²⁰ +32.6 (*c* 0.5, CH₂Cl₂) for 92 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 0.84-1.77 (m, 10H),


1.98-2.03 (m, 3H), 2.39-2.46 (m, 4H), 2.95 (br s, 1H), 3.87 (br s, 1H), 6.79 (t, J = 4.2 Hz, 1H). Chiralcel OJ, hexane/i-PrOH = 90/10, 0.8 mL/min, 230 nm, $t_{major} = 6.50$ min, $t_{minor} = 7.17$ min.










(R,E)-2-benzylidene-3-phenylcyclopentanone **5ka**^[2] (Fig. 2, entry 18). [α]_D²⁰ +182.4 (c 0.60, CHCl₃) for 62 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 2.16-2.19 (m, 1H), 2.34-2.45 (m, 3H), 4.53 (d, J = 6.8 Hz, 1H), 7.21-7.35 (m, 10H), 7.268 (d, J = 1.6 Hz, 1H). MS (EI) m/z (%): 249.1 (M+H, 100); HRMS (Micromass LCT) Calcd. for C₁₈H₁₇O: 249.1279; Found: 249.1283. Chiralcel AD, hexane/i-PrOH = 90/10, 0.8 mL/min, 254 nm, t_{major} = 9.13 min, t_{minor} = 9.83 min.






(*R*)-2-(hydroxy(phenyl)methyl)cyclopent-2-enone 3k.^[11] [α]_D²⁰ -7.8 (*c* 0.70, CH₂Cl₂) for 13 % ee. ¹H NMR (400 MHz, CDCl₃, TMS): δ 2.45-2.47 (m, 2H), 2.58-2.60 (m, 2H), 3.48 (br s, 1H), 5.57 (s, 1H), 7.26-7.40 (m, 6H). Chiralcel OJ, hexane/*i*-PrOH = 90/10, 1.0 mL/min, 230 nm, t_{major} = 24.33 min, t_{minor} = 21.83 min.







References

- 1. P. Wessig, G. Müller, Australian Journal of Chemistry 61, 569 (2008).
- 2. T. Gendrineau, J. -P. Genet, S. Darses, Org. Lett. 12, 308 (2010).
- 3. N. T. McDougal, S. E. Schaus, J. Am. Chem. Soc. 125, 12094 (2003).
- 4. Z. Shafiq, L. Liu, Z. Liu, D. Wang, Y. Chen, Org. Lett. 9, 2525 (2007).
- 5. C. K.-W. Kwong, R. Huang, M. Zhang, M. Shi, P. H. Toy, *Chem. Eur. J.* **13**, 2369 (2007).
- 6. M. Shi, X.-G. Liu, Org. Lett. 10, 1043 (2008).
- 7. (a) A. Berkessel, K. Roland, J. M. Neudoerfl, *Org. Lett.* **8**, 4195 (2006). (b) A. Lattanzi, *Synlett* 2106 (2007).
- 8. T. Kataoka, T. Iwama, S. Tsujiyama, T. Iwamura, S. Watanabe, *Tetrahedron* **54**, 11813 (1998).
- 9. (a) M. Bailey, I. Staton, P. R. Ashton, I. E. Marko, W. D. Ollis, *Tetrahedron: Asymmetry* 2, 495 (1991). (b) M. Bailey, I. E. Marko, W. D. Ollis, *Tetrahedron Lett* 32, 2687 (1991).
- 10. V. K. Aggarwal, A. Mereu, *Chem. Commun.* 2311 (1999).
- 11. A. Bugarin, B. T. Connell, Chem. Commun. 2644 (2010).




Fig. S1. X-ray crystal data of product (a*S*,*S*)-2a.

The crystal data of (a*S*,*S*)-**2a** have been deposited in CCDC with number 798781. Empirical formula: $C_{27}H_{21}I_2N_3OPd$; Formula weight: 763.67; Temperature: 296(2) K; Wavelength: 0.71073 Å: Crystal system, space group: Orthorhombic, P2(1)2(1)2(1); Unit cell dimensions: a = 9.0426(5) Å, alpha = 90 deg. b = 15.0498(9) Å, beta = 90 deg. c = 19.5924(11) Å, gamma = 90 deg. Volume: 2666.3(3) Å³; Z, Calculated density: 4, 1.902 Mg/m³; F(000): 1456; Crystal size: 0.39 x 0.23 x 0.09 mm; Final R indices [I>2sigma(I)], R1 = 0.0496, wR2 = 0.1067; R indices (all data) R1 = 0.0645, wR2 = 0.1171. Selected bond distances (Å) and angles (°): I1-Pd1 2.5771(12), I2-Pd1 2.6709(+11), N1-Pd1 2.068(8), C20-Pd1 1.935(11), N2-C20 1.341(14), N3-C20 1.376(14), N1-C11 1.283(14), I1-Pd1-I2 96.67(4), N1-Pd1-C20 84.7(4), Pd1-C20-N3 122.8(8), C20-N3-C10-C1 -116.9(13), C20-N3-C10-C9 66.9(16), C10-C9-C11-N1 -45.1(18).




Fig. S2. X-ray crystal data of product (R)-5hf.

The crystal data of (*R*)-**5hf** have been deposited in CCDC with number 822886. Empirical formula: $C_{19}H_{16}CINO_3$; Formula weight: 341.78; Temperature: 296(2) K; Wavelength: 0.71073 Å: Crystal system, space group: Monoclinic, P2(1); Unit cell dimensions: a = 11.1242(5) Å, alpha = 90 deg. b = 6.2039(3) Å, beta = 111.5220(10), c = 13.0579(6) Å, gamma = 90 deg. Volume: 838.34(7) Å³; Z, Calculated density: 2, 1.354 Mg/m³; F(000): 356; Crystal size: 0.46 x 0.38 x 0.32 mm; Final R indices [I>2sigma(I)], R1 = 0.0337, wR2 = 0.0818; R indices (all data) R1 = 0.0394, wR2 = 0.0855.

A possible catalytic cycled for the kinetic resolution.